Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Discover a variety of high-fiber, low-calorie weight-loss snacks that won't leave you feeling deprived for a successful weight-loss journey.

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...

As a parent, it’s natural to want to track her progress, especially when it comes to height and weight. Growth charts ... and ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Healthcare Realty Trust gets an initial rating of hold, agreeing with the consensus today. Upside factors include macro data ...

The Standard's journalism is supported by our readers. When you purchase through links on our site, we may earn an affiliate commission. A healthy diet and regular exercise are the two best tools ...

One study found that people who followed a Mediterranean or green Mediterranean diet had more weight loss and reduced waist ... Fan Y, et al. Comparison of bioelectrical body and visceral fat ...

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new class of weight-loss drugs.

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.

Researchers trained a large language model to read medical charts, looking for signs that ... (e.g., either "reduced appetite" or "no weight loss") as indicating that follow-up had happened ...

Weight loss refers to a decrease in your overall body weight from muscle, water, and fat loss. Fat loss refers to weight loss from fat only, and it’s a more specific and healthy goal than ...